S
creening for prostate cancer with prostate-specific antigen (PSA) is controversial because there is inconclusive evidence that regular testing reduces mortality. [1] [2] [3] Until clinical trials 4, 5 determine whether there is a net benefit, professional organizations recommend that physicians inform men of the potential risks and benefits of testing through informed or shared decision making. [6] [7] [8] [9] [10] These risks include potential harms, such as false-positive results and unnecessary anxiety, biopsies, and potential treatment complications for some cancers whose natural course may not lead to morbidity and mortality. 10 Despite its uncertain efficacy, PSA testing has become widespread. [11] [12] [13] [14] [15] [16] It has become even more prevalent than colorectal cancer screening, an intervention with proven efficacy and unanimous support among professional organizations. 14, 16 Although physicians have contributed to the widespread uptake of PSA testing among men, [11] [12] [13] [14] [15] [16] it is unknown just how many U.S. physicians have taken the PSA test themselves. One study in Victoria, Australia, found evidence to support high levels of PSA testing (45%) among physicians there. 17 In this study, we determined the prevalence of personal PSA testing among a national sample of urologists, family physicians and Internists.
METHODS
We obtained institutional board review approval from the University of Texas-Houston Health Sciences Center to draw a nationwide random sample of physicians. The sample was stratified by specialty from the Official ABMS Directory of Board-Certified Medical Specialists 2000, 32nd edn, Vols. 1-4. We determined physician eligibility and mailed surveys and postcard reminders as described previously. 18 Eligible physicians practiced medicine at least 20 hours/week, cared for men aged 40 and older, and were not in residency training. In 2000, we surveyed 273 eligible internists, 249 family physicians, and 247 urologists. We received completed surveys from 139 internists, 160 family physicians, and 151 urologists (overall response rate: 59%). For our analysis, we dropped 84 women, 2 men who reported a personal history of prostate cancer, and 4 men who did not respond to that question, leaving 96 Internists, 118 family physicians, and 146 urologists. Because family physicians and internists had similar demographic characteristics and responses, we combined them as ''nonurologists'' and compared them with urologists. We asked physicians: ''Have you ever undergone prostate cancer screening with prostate specific antigen?'' We also ascertained respondents' age, years with a medical degree, race/ ethnicity, and marital status.
For men at average risk for prostate cancer, professional organizations recommend offering PSA testing beginning at age 50 [6] [7] [8] [9] [10] ; therefore, the primary focus of our analysis was on male physicians aged 50 and older since they would be potential candidates for PSA testing. As a secondary focus, we examined white male physicians under the age of 50. Men under age 50 are not candidates for PSA testing unless they are at a higher than average risk for prostate cancer (e.g., African Americans). Therefore, urologists and nonurologists under the age of 50 who are white would not be expected to have undergone PSA screening themselves. We used w 2 tests to compare the frequency distributions.
RESULTS
The demographic characteristics of survey respondents are shown in Table 1 . Of male physicians aged 50 and older, 87% (95% confidence interval: 81.2% to 91.6%) (155/178) reported having had a screening PSA test. Among physicians aged 50 and older, more urologists (95%) than nonurologists (78%) reported a PSA test (Table 2) . Among white male physicians under the age of 50, 21% (95% confidence interval: 14.5% to 28.0%) (31/150) reported a PSA screening test, and more urologists (40%) than nonurologists (13%) reported being screened (Table 2) .
DISCUSSION
The 2000 U.S. National Health Interview Survey (NHIS) found that 57% of men aged 50 and older with no history of prostate cancer reported ever having had a PSA test. 16 Although NHIS data are weighted to provide estimates representative of men in the general population 16 and our data are not (and therefore may have been skewed by incomplete survey participation), our results suggest that PSA screening may be more widespread among physicians than in the general population. Despite professional guidelines against offering the PSA test to men under the age of 50 in the absence of risk factors for prostate cancer, we found a high percentage of physicians under the age of 50 who had undergone screening. The 2001 Behavioral Risk Factor Surveillance System (BRFSS) survey 14 found that 34% of the men in the general population aged 40 to 49 years reported having had a PSA test. The prevalence of PSA screening that we found for white urologists under the age of 50 is higher than would be expected if they were testing based on a family history of prostate cancer, which is found in only 10% of men in the general population. 19 Our findings suggest that physicians may be requesting and, at the least, are not refusing PSA screening when offered, which in turn suggests that physicians believe that the potential harms of PSA testing do not outweigh the potential benefits. It is possible that they may be adhering to perceived standards of care, 14, 15 believe that PSA screening is beneficial, 15 or appreciate the psychological reassurance of a negative PSA screening test result. 20 Compared with nonurologists, more urologists reported undergoing PSA screening, regardless of age. We previously found that urologists are less likely to consider that the un- 
